Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

Charlotte Steffensen; Merete Lund Mægbæk; Peter Laurberg; Marianne Andersen; Caroline Kistorp; Helene Nørrelund; Jakob Dal; Jens Otto Lunde Jørgensen

Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

Charlotte Steffensen, Merete Lund Mægbæk, Peter Laurberg, Marianne Andersen, Caroline Kistorp, Helene Nørrelund, Jakob Dal, Jens Otto Lunde Jørgensen

Institut for Klinisk Medicin

Abstract

Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patientsTreatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

Bidragets oversatte titel	Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	176
Udgave nummer	1
Sider (fra-til)	58-60
Antal sider	3
ISSN	0041-5782
Status	Udgivet - 6 jan. 2014

Citationsformater

@article{8d7531a9a57046149d006bda0c71c772,

title = "Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktin{\ae}mi",

abstract = "Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patientsTreatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.",

author = "Charlotte Steffensen and M{\ae}gb{\ae}k, {Merete Lund} and Peter Laurberg and Marianne Andersen and Caroline Kistorp and Helene N{\o}rrelund and Jakob Dal and J{\o}rgensen, {Jens Otto Lunde}",

year = "2014",

month = jan,

day = "6",

language = "Dansk",

volume = "176",

pages = "58--60",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "1",

}

TY - JOUR

T1 - Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

AU - Steffensen, Charlotte

AU - Mægbæk, Merete Lund

AU - Laurberg, Peter

AU - Andersen, Marianne

AU - Kistorp, Caroline

AU - Nørrelund, Helene

AU - Dal, Jakob

AU - Jørgensen, Jens Otto Lunde

PY - 2014/1/6

Y1 - 2014/1/6

N2 - Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patientsTreatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

AB - Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patientsTreatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

M3 - Tidsskriftartikel

C2 - 24629610

SN - 0041-5782

VL - 176

SP - 58

EP - 60

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 1

ER -

Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi

Abstract

Fingeraftryk

Citationsformater